Purpose: The aim of this study was to evaluate a candidate haemostat (WoundStat™), down-selected from previous in vitro studies, for efficacy as a potential skin decontaminant against the chemical warfare agent pinacoyl methylfluorophosphonate (Soman, GD) using an in vivo pig model.
Introduction
Military personnel are constantly exposed to the risk of traumatic, penetrating injury on the battlefield (1-4) and various haemostatic treatments have been evaluated in combat settings (5) (6) (7) (8) . Should wounding occur in a chemically contaminated environment, such as after hostile deployment of a chemical warfare agent (CWA), the use of haemostatic treatments would be complicated by the need to decontaminate the wound site. Of major concern is whether the use of a haemostat on a chemically contaminated wound would increase systemic absorption. Rather than using separate strategies to arrest haemorrhage and decontaminate a wound site, the development of a product that simultaneously arrests haemorrhage and decontaminates wounds would have clear advantages. Studies involving the use of CWAs to evaluate the efficacy of potential medical countermeasures, by necessity, use animal models to indicate what would happen in humans. For studies involving the dermal exposure route, the pig is generally accepted as being the most representative model for man (9) (10) .
Previous in vitro studies have demonstrated that haemostatic products may retain the ability to clot blood in the presence of CWAs and that certain products (based on absorptive powders) are able to effectively decontaminate CWAs from normal and superficiallydamaged skin (11) (12) (13) . One product, WoundStat™, was identified as being particularly effective in terms of its ability to decontaminate CWAs from undamaged or superficiallydamaged skin. The purpose of the current study was to extend the evaluation of WoundStat™ to an in vivo, non-haemorrhaging wound model using the CWA soman (pinacoyl methylfluorophosphonate).
Methods

Chemicals
The synthesis, use and destruction of soman (GD; pinacoyl methylfluorophosphonate) was conducted in accordance with the Chemical Weapons Convention (1996) . Radiolabelled GD was synthesised by TNO (Rijswijk, Netherlands) and had a radiochemical purity >97% (as determined by radiometric HPLC analysis). The chemical purity of unlabelled GD (supplied by Dstl Detection Department, Salisbury, Wiltshire) was reported to be >97% (as measured by nuclear magnetic resonance spectroscopy). Radiolabelled and unlabelled GD were mixed in appropriate proportions to give a nominal activity of approximately 5 µCi µL -1 . Gold and opaque plastic vials) were purchased from Perkin-Elmer (Chandler's Ford, Hampshire). All other chemicals were analytical grade and were purchased from the Sigma Chemical Company (Poole, Dorset).
Treatment
The haemostat WoundStat™ was purchased from TraumaCure, Inc. (Bethesda, MD). undisturbed for the duration of the study. Animals in the control (untreated) group were exposed to GD but not subject to the application of WoundStat™. Arterial blood samples were taken into both sodium EDTA tubes and sodium citrated tubes at regular intervals both pre and post GD challenge. Blood samples taken into sodium EDTA tubes were used for haematocrit quantification and analysis of whole blood cholinesterase activity. Blood samples taken into sodium citrate tubes were used for radiometric quantification.
Animal model
Terminal procedures
Euthanasia was achieved by i.v. bolus of Dolethal® (sodium pentobarbitone; 6 mL, 200 mg mL -1 ) at 6 h (surviving animals) or 15 minutes after the onset of apnoea. The dosed ear was then carefully removed and the decontaminant (where appropriate) removed from the skin surface and placed in 16 mL of scintillation counting fluid (Ultima Gold, PerkinElmer LAS (UK) Ltd., Buckinghamshire, UK). The dosing template was removed and placed in 20 mL isopropanol. The skin surface was swabbed with cotton wool (to remove any residual GD) and the swab was placed in 16 mL of isopropanol. The skin exposure site was excised, and the periphery and the central area of the dosing site were separated to enable determination of skin surface spread from the central dosing area. These skin samples were placed in 16 mL Soluene-350. Each animal was then exsanguinated prior to post-mortem examination. Major organs (brain, heart, kidney, liver, lung, pancreas and spleen) were removed, weighed and frozen for subsequent radiometric analysis.
Whole blood cholinesterase measurement
A modified Ellman assay (14) was used to quantify whole blood cholinesterase. Briefly, enzyme activity was measured via reaction of thiocholine with 5,5-dithiobis-(2 nitrobenzoic) acid (DTNB). Prior to analysis, samples of arterial whole blood had been stored at -20°C for at least a week in sodium EDTA tubes. A 25 µL sample of whole blood was made up to 5 mL in a pH 8.0 phosphate buffer. A 1 mL sample of the resulting blood solution was incubated at 30°C in a cuvette containing both acetylthiocholine iodide (1 mM) and DTNB (0.25 mM).
The reaction, monitored at 412 nm, was measured over a 10-minute period using a Biochrom Ultrospec 6300 spectrophotometer. Appropriate blanks (substrate and tissue) were run simultaneously with the test samples and were subtracted from the test reaction.
Radiometric analysis
Vials containing the dosing chamber, skin surface swab, dissolved skin were stored at room temperature (with occasional shaking) for up to two weeks, after which aliquots (250 µL)
were removed into 5 mL of scintillation fluid. Organ samples (approximately 0.1 g) were dissected in triplicate, placed into 2 mL Soluene within a glass scintillation vial and heated at 60ºC for a period of 4 hours. After cooling to room temperature, 20 mL of Ultima gold liquid scintillation fluid was added to each vial. The method described by Moore (15) was used for blood sample preparation, as follows: a blood sample (0.4 mL) was placed into a glass liquid scintillation vial. To this 1 mL of a Soluene and isopropanol (1:2 ratio) mixture was added whilst the vial was swirled gently. Each vial was then heated at 60ºC for 2 hours. After cooling, 0.5 mL of 30% hydrogen peroxide was added with gentle agitation until foaming had Absorption of 14 C-GD was measured according to the appearance of radiolabel within the circulating blood volume at defined time points after 14 C-GD challenge to the dosing site.
Radiometric analyses were grouped as external quantification, local quantification and internal quantification. External quantification grouped the unabsorbed fraction of GD and included the portions of radioactivity remaining on the skin surface or sequestered into the WoundStat™ treatment. Local quantification grouped radioactivity recovery within the skin at the dosing site and at the periphery of the dosing site. Internal quantification grouped the portions of radioactivity located in the blood, liver, kidney, pancreas, spleen, heart, lung and brain. Any radioactivity unaccounted for was assumed to have either volatilised from the skin surface or to have been present in unsampled organs.
Statistical analysis
GraphPad Prism version 6.01 for Windows (GraphPad Software) was used for normality testing, statistical analysis and graphical presentation of the data. Data were assessed for normal distribution using a D'Agostino and Pearson omnibus normality test and a Gaussian non-linear regression curve fit. Significance was predefined at an alpha-level of 0.05.
Survival fractions and survival curve were analysed using the Kaplan-Meier (log-rank) 
Results
Survival and gross clinical observations
Application of GD to damaged skin in vivo resulted in the rapid onset of multiple observable (Table 1) or physiological (Table 2 ) signs of nerve agent poisoning. In addition, only one of the animals in the GD-exposed untreated group survived to six hours post-exposure ( Figure   1 ) and median survival time differed significantly between the control and GD-exposed untreated groups (Figure 2 ). Two animals in the GD-exposed WoundStat™-treated group survived until the end of the study period ( Figure 1 ). Signs of nerve agent poisoning were also observed in these animals, although there tended to be a longer latency in the onset of signs when compared to the untreated group (Table 1 ). In addition, there was no significant difference in median survival time between the GD-exposed WoundStat™-treated group and the unexposed control group (Figure 2 ). All six animals in the control group survived the sixhour study duration and showed no sign of GD intoxication.
Toxicodynamics
The clinical signs observed in the GD-exposed untreated group were accompanied by a rapid depression of whole blood cholinesterase to less than 5% of baseline values by 15 minutes post exposure ( Figure 3 ) and an increase in whole blood haematocrit (Figure 4) . Similarly, the GD-exposed WoundStat™-treated group exhibited rapidly decreasing whole blood cholinesterase ( Figure 3 ) and increased haematocrit (Figure 4 ) during the study.
Toxicokinetics
Blood levels of 14 C-GD reached a maximum within 10 minutes of GD challenge for both untreated and WoundStat™ treated groups ( Figure 5 ). In the WoundStat™ treatment group, the amount of 14 C-GD in the blood had halved by 20 minutes post-exposure and remained constant at this level for the study duration. In contrast, in the untreated group, the amount of 14 C-GD in the blood steadily increased as the study progressed. Comparison of whole blood cholinesterase and the amount of 14 C-GD in the blood indicated that a blood recovery of >15 µg 14 C-GD resulted in maximum cholinesterase inhibition ( Figure 6 ).
Distribution
Upon completion of the untreated studies, the majority of the applied 14 C-GD was located either on the skin surface or within the skin at the dosing site, while a smaller portion of radioactivity was recovered from the periphery of the dosing site (Figure 7a 
Discussion
The in vivo studies reported here used terminally anaesthetised large white pigs, with the GD challenge applied to the ear of the animal. This model and dosing site has been used previously for the assessment of countermeasures against nerve agents (17, 18) . In contrast to the previous studies, this is, to the authors' knowledge, the first time that the skin had been damaged to allow a more rapid ingress of chemical warfare agent, in order to model a nonhaemorrhaging, contaminated wound.
11
The current study has shown that the use of WoundStat™ as a decontaminant on damaged (non-haemorrhaging) pig ear skin was unable to protect against GD toxicity. Most importantly, however, the use of WoundStat™ did not enhance the toxicity of GD.
WoundStat™ decontamination 30 seconds post GD challenge sequestered 68% ± 26% of the 14 C-GD applied. Contemporary studies evaluating WoundStat™ as a decontaminant against the vesicating agent sulphur mustard gave increased recoveries of 99% ± 8% (19) . Given that similar experimental procedures were used, it is likely that the differences in recovery are ascribable to differences in physicochemical properties, such as volatility, between the two CWAs. In the case of GD, it is likely that a proportion volatilised or was absorbed prior to decontaminant application and was therefore not available for absorption by WoundStat™. Similar levels of WoundStat™ 14 C-GD decontamination were measured during in vitro studies for both damaged and undamaged skin (20) , indicating that decontamination should be carried out as rapidly as possible to limit the percutaneous absorption of GD.
Decontamination with WoundStat™ substantially reduced the amount of 14 C-GD remaining on the skin surface (1.8% ± 1.9% versus 16.7% ± 20.8% for treated and untreated animals, respectively) and within the skin (7.5% ± 3.8% versus 42.7% ± 22.7%). The 14 C-GD remaining on or within the skin would not have impacted upon the observed and measured systemic toxicity. The systemic toxicity can be attributed to the internally absorbed dose of GD. WoundStat™ treatment resulted in a reduction of internally measured 14 C-GD by approximately 0.5% (1.2% ± 0.3%versus 1.7% ± 0.6%). This equated to a 30% reduction in systemically recovered material.
Despite this substantial reduction, whole blood cholinesterase measurements and 14 C-GD blood levels were similar whether or not WoundStat™ decontamination had been carried out. Both experimental groups had animals that had high initial levels of 14 C-GD in the blood, associated with rapidly declining whole blood cholinesterase. These animals did not survive for more than 45 minutes into the exposure period. In the WoundStat™ decontaminated animals that survived the initial period, 14 C-GD blood levels and whole blood cholinesterase levels stabilised by 30 minutes and remained constant for the study duration. Conversely, for those animals in the untreated group that survived the initial period, cholinesterase levels remained below 5% of baseline values, whereas 14 C-GD blood levels increased steadily until death or study termination. For both the untreated and the WoundStat™ decontaminated animals, haematocrit levels increased steadily over the exposure duration, whereas for the control group haematocrit levels were consistently lower and remained constant. Importantly, although WoundStat™ was not an effective decontaminant against GD, it did not exacerbate GD toxicity. One of the major concerns regarding the treatment of GD-contaminated wounds was whether the use of a haemostat would increase the systemic absorption of GD. The current study found that WoundStat™ had no such effect.
In the current study, WoundStat™ was evaluated as a decontaminant in the absence of additional medical countermeasures. Should nerve agent exposure be confirmed, then further specific medical countermeasures would be employed alongside decontamination. The benefit of using decontaminants to increase survival times, allowing longer therapeutic windows for specific medical countermeasures to be employed, has been described previously (21) .
Conclusion
The current study has shown that use of the haemostat WoundStat™, as a decontaminant for the nerve agent GD, was unable to protect against the effects of GD toxicity. Importantly, however, the findings of this study indicate that the use of WoundStat™ in GD-contaminated 13 wounds does not exacerbate GD toxicity. A. Total Recovery. Sampled compartments were: WoundStat™-sequestered (treated animals only), GD remaining on damaged skin surface, GD present with the skin directly under the dosing site, GD present within the skin adjacent to the dosing site, GD absorbed into the dosing assembly and GD recovered from sampled organs (detailed in Figure 6 ).
Compartments were sampled either after the animal had succumbed to GD toxicity or upon completion of the 6 hour study duration.
B. External Quantification. Compartments shown: WoundStat™-sequestered (treated animals only), GD remaining on damaged skin surface and GD absorbed into the dosing assembly.
C. Local Quantification. Compartments shown: GD present with the skin directly under the dosing site and GD present within the skin adjacent to the dosing site.
D. Internal Quantification. Compartment shown: GD recovered from sampled organs (detailed in Figure 6 ).
All values are mean ± standard deviation of n=6 animals. * †Statistically significant (p<0.05) differences in the respective parameters between the Treated and Untreated groups. Sampled internal organs were heart, spleen, lung, pancreas, liver, kidney, blood and brain.
Organs were harvested after either the animal had succumbed to GD toxicity or upon completion of the 6 hour study duration. Recovery from within the systemic circulation was determined from the final blood sample taken prior to the end of each study. All values are mean ± standard deviation of n=6 animals. *Statistically significant (p<0.05) difference between the Treated and Untreated groups.
